The purpose of this study is to evaluate the safety, tolerability and effectiveness of rilzabrutinib (also known as SAR444671) compared to a placebo in adults with moderate-to-severe asthma.
The purpose of this study is to build a tool to support medical decision-making and the integration of a validated clinical-prediction model into routine care for individuals with chronic obstructive pulmonary disease (COPD).
The purpose of this study is to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
The purpose of this study is determine if a fixed-dose combination of the drugs macitentan and tadalafil is more effective than therapy with macitentan or tadalafil alone to treat pulmonary arterial hypertension.
The purpose of this study is to determine the lung and immune function benefits of stopping vaping for 72 hours in young adults who use e-cigarettes containing nicotine. The study also aims to determine if telling participants of their own personalized changes to their lung and immune function following the 72 hour abstinence period affects their motivation in quitting vaping.
The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).
People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.
Sleep Apnea (SA) is a disorder that causes pauses in breathing during sleep that expose the heart to oxygen deprivation. It is common in patients with heart failure (HF) where it is associated with increased risk of hospitalizations and death. It is not known however whether treating SA reduces these risks. This study is looking at whether a respiratory device known as Adaptive Servo Ventilation (ASV) can reduce the rate of cardiovascular hospitalizations and death in subjects with HF and SA.
The purpose of this study is to understand asthmatic patients' knowledge, perceptions and viewpoints about using a telehealth approach to manage their asthma conditions.
The purpose of this study is to assess the safety and efficacy of pulsed inhaled nitric oxide versus placebo in subjects at risk for pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy.
The purpose of this study is to test the safety and efficacy of an inhaled medication (CSJ117) compared with a placebo for improving lung function in patients with inadequate control of moderate to severe asthma.
The purpose of this study is to determine if dupilumab is effective and safe in decreasing episodes of severe breathing difficulties in patients with allergic bronchopulmonary aspergillosis (ABPA).
The purpose of this study is to determine if BC residents receive, understand and implement public health messages related to wildfire smoke exposures, and to better understand the reach of these messages and identify opportunities for future improvement.
The purpose of this study is to understand how patients with asthma and COPD have been affected by the changes to the health care system as a result of the COVID-19 pandemic.
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with pulmonary hypertension (PH) who previously participated in controlled clinical studies with bardoxolone methyl.
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with connective tissue disease-associated pulmonary arterial hypertension to determine the recommended dose range and evaluate the change from baseline in 6-minute walk distance (6MWD) following 24 weeks of study participation.
This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate the effect of a fixed 30 mg dose of benralizumab administered subcutaneously every 4 weeks on allergen-induced inflammation in subjects with mild atopic asthma challenged with an inhaled allergen.
The purpose of this study is to evaluate the long-term safety, efficacy and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study.
This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).